Local Institution

Kansas City, Kansas 66160

0 studies enrolling now · 15 studies all time

What they study most

Acute Coronary Syndromes, Bipolar Disorder, Blast Crisis, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Giant Cell Arteritis, HIV Infections, Hypertension, Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive, Leukemia, Lymphocytic, Acute, L2, Leukemia, Myeloid, Chronic

Studies at this site

• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) — Withdrawn before enrolling
• Aripiprazole Open-Label, Safety and Tolerability Study — Completed
• Aripiprazole in Adolescents With Schizophrenia — Completed
• Aripiprazole in Children and Adolescents With Bipolar I Disorder — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• Atazanavir for HIV Infected Individuals: An Early Access Program — NO_LONGER_AVAILABLE
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early